Odonate Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview

Odonate

26/07/2021 13:50

* Odonate Therapeutics Inc  ODT.OQ   ODT.O  is expected to show
a no change in quarterly revenue when it reports results on July
28 (estimated). 
​* Refinitiv's mean analyst estimate for Odonate Therapeutics
Inc is for a loss of 33 cents per share. For the same quarter
last year, the company reported a loss of $1.09 per share.
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is no "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Odonate
Therapeutics Inc is $4​, about 4% above​ its last closing price
of $3.84. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.80       -0.81      -0.90     Missed  -11.3
 Dec. 31 2020  -0.79       -0.78      -0.83     Missed  -6.1
 Sep. 30 2020  -0.92       -0.95      -0.93     Beat    2.2​
 Jun. 30 2020  -0.96       -0.98      -1.09     Missed  -11.3
 Mar.          -1.01​      -1.02      -0.99     Beat    2.8​
 31​ 2020​                                              
 Dec. 31 2019  -0.98       -0.99      -0.90     Beat    9.2​
 Sep. 30 2019  -1.10       -1.06      -0.88     Beat    16.7
 Jun. 30 2019  -1.26       -1.24      -1.15     Beat    7.4
 This summary was machine generated July 26 at 12:50 GMT.  All
figures in US dollars unless otherwise stated